Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) announced that its shareholders approved all motions on the agenda for the ordinary part of the Annual General Meeting (AGM) 2026 held today, April 23, 2026. The approvals included the election of George Garibaldi and Paolo Zocchi as new, independent, and non-executive Board members.
The motions on the agenda for the extraordinary part of the meeting were not put to a vote, as the required quorum was not reached. The company did not disclose the specific extraordinary motions, but such items typically involve significant corporate actions such as capital increases or amendments to the company's articles of incorporation.
Chris Martin, Chairman of the Board of Directors of Newron, expressed gratitude to shareholders for their trust and welcomed the newly elected board members. He also thanked Patrick Langlois and Luca Benatti, who stepped down from the Board after long-standing service, for their support of Newron.
Newron is a biopharmaceutical company focused on developing novel therapies for patients with diseases of the central and peripheral nervous system (CNS). Headquartered in Bresso near Milan, Italy, the company has a strong track record of advancing neuroscience-based treatments from discovery to market.
The company's lead compound, evenamide, is a first-in-class glutamate modulator with potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently being developed in the global pivotal ENIGMA-TRS Phase III development program. Clinical trial results to date demonstrate benefits in TRS and poorly responding patient populations, with significant improvements across key efficacy measures increasing over time, as well as a favorable safety profile uncommon for available antipsychotic medications.
Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. The company's first marketed product, Xadago®/safinamide, has received marketing authorization for the treatment of Parkinson's disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The product is commercialized by Newron's partner Zambon, with Supernus Pharmaceuticals holding marketing rights in the U.S., and Meiji Seika responsible for development and commercialization in Japan and other key Asian territories.
For more information, visit www.newron.com.
